Adalimumab therapy for childhood uveitis
- PMID: 17011337
- DOI: 10.1016/j.jpeds.2006.04.058
Adalimumab therapy for childhood uveitis
Abstract
Fourteen children with uveitis (9 JIA associated and 5 idiopathic) were treated with adalimumab for an average of 18.1 months. Inflammation decreased in 21/26 eyes (80.8%), 4 eyes remained stable (15.4%), and 1 worsened (3.8%) (P < .001; 2 tailed paired Wilcoxon rank sum test). No significant adverse events occurred.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical